{
    "clinical_study": {
        "@rank": "50252", 
        "arm_group": [
            {
                "arm_group_label": "ACT-129968 Tablet/Capsules", 
                "arm_group_type": "Experimental", 
                "description": "Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period."
            }, 
            {
                "arm_group_label": "ACT-129968 Capsules/Tablet", 
                "arm_group_type": "Experimental", 
                "description": "Subjects attend two treatment periods. In the first treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as capsules (2 capsules, 250 mg each) in the fasted state. In the second treatment period subjects receive a single, oral dose of ACT-129968 500 mg administered as a tablet (1 tablet, 500 mg each) in the fasted state. There is a 7-9 day washout period between the first treatment period and the second treatment period."
            }
        ], 
        "brief_summary": {
            "textblock": "To explore the pharmacokinetics (PK) of a single dose of two different formulations of\n      ACT-129968, i.e., tablet versus capsule and to evaluate the safety and tolerability of a\n      single dose of two different formulations of ACT-129968, i.e., tablet versus capsule."
        }, 
        "brief_title": "Study in Healthy Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Formulations of ACT-129968", 
        "completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "condition": "Healthy", 
        "detailed_description": {
            "textblock": "A total of 10 female and 10 male healthy subjects will be enrolled and will attend two\n      treatment periods, separated by a 7-9 day washout. Over these two periods, two formulations\n      of ACT-129968 (Treatment A:  two capsules, 250 mg each; Treatment B: one tablet, 500 mg)\n      will be administered in the sequence A/B or B/A to 10 subjects (5 females and 5 males) per\n      sequence as determined by randomization."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed informed consent in the local language prior to any study-mandated procedure.\n\n          -  Women must have a negative serum pregnancy test at screening and a negative urine\n             pregnancy test pre-dose on Day-1 of each treatment period.\n\n          -  Women of childbearing potential must consistently and correctly use (from screening,\n             during the entire study, and for at least 28 days after last study drug intake) a\n             reliable method of contraception with a failure rate of < 1% per year, be sexually\n             inactive, or have a vasectomized partner. Women not of childbearing potential are\n             defined as post-menopausal (i.e., spontaneous amenorrhea for at least\n\n             1 year without an alternative medical cause) or surgically or naturally sterile.\n\n          -  No clinically significant findings on the physical examination at screening.\n\n          -  Body mass index (BMI) of 18.0 to 28.0 kg/m^2 (inclusive) at screening.\n\n          -  Systolic blood pressure (SBP) 100-145 mmHg, diastolic blood pressure (DBP) 50-90\n             mmHg, and pulse rate (PR) 45-90 bpm (inclusive), measured on the dominant arm\n             (dominant arm = writing arm) after 5 minutes in the supine position at screening.\n\n          -  12-lead electrocardiogram (ECG) without clinically relevant abnormalities, measured\n             after 5 minutes in the supine position at screening.\n\n          -  Hematology, clinical chemistry, and urinalysis test results not deviating from the\n             normal range to a clinically relevant extent at screening.\n\n          -  Negative results from urine drug screen and breath alcohol test at screening and on\n             admission to the unit (Day-1) in Period 1 and Period 2.\n\n          -  Ability to communicate well with the investigator, in the local language, and to\n             understand and comply with the requirements of the study.\n\n        Exclusion Criteria:\n\n          -  Pregnant or lactating women.\n\n          -  Known allergic reactions or hypersensitivity to any excipient of the drug\n             formulation(s).\n\n          -  History or clinical evidence of any disease and/or existence of any surgical or\n             medical condition which might interfere with the absorption, distribution,\n             metabolism, or excretion of the study drug (appendectomy and herniotomy allowed,\n             cholecystectomy not allowed).\n\n          -  Previous history of fainting, collapse, syncope, orthostatic hypotension, or\n             vasovagal reactions.\n\n          -  History or clinical evidence of allergic rhinitis or asthma.\n\n          -  Veins unsuitable for intravenous puncture on either arm (e.g., veins that are\n             difficult to locate, access, or puncture, veins with a tendency to rupture during or\n             after puncture).\n\n          -  Previous exposure to the study medication.\n\n          -  Treatment with another investigational drug within 3 months prior to screening or\n             participation in more than four investigational drug studies within 1 year prior to\n             screening.\n\n          -  History or clinical evidence of alcoholism or drug abuse within the 3-year period\n             prior to screening.\n\n          -  Excessive caffeine consumption, defined as 800 mg per day at screening.\n\n          -  Alcohol consumption of > 21 units/week or > 3 units/day.\n\n          -  Smoking within 3 months prior to screening.\n\n          -  Previous treatment with any prescribed or over-the-counter medications (including\n             herbal medicines such as St John's Wort) within 2 weeks prior to first study drug\n             administration.\n\n          -  Loss of 250 mL or more of blood within 3 months prior to screening.\n\n          -  Positive results from the hepatitis serology (Hepatitis B surface antigen and\n             anti-hepatitis C virus), except for vaccinated subjects or subjects with past but\n             resolved hepatitis (defined as positive finding for antibodies but negative findings\n             for antigens), at screening.\n\n          -  Positive results from the human immunodeficiency virus serology at screening.\n\n          -  Any circumstances or conditions, which, in the opinion of the investigator, may\n             affect full participation in the study or compliance with the protocol.\n\n          -  Legal incapacity or limited legal capacity at screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "45 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "June 12, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01877629", 
            "org_study_id": "AC-060-104"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "ACT-129968 Tablet/Capsules", 
                    "ACT-129968 Capsules/Tablet"
                ], 
                "description": "ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist", 
                "intervention_name": "ACT-129968 500 mg  Tablet", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "ACT-129968 Tablet/Capsules", 
                    "ACT-129968 Capsules/Tablet"
                ], 
                "description": "ACT-129968, a tetrahydropyridoindole derivative, is a chemoattractant receptor homologous molecule expressed on T helper 2 cells (CRTH2) antagonist", 
                "intervention_name": "ACT-129968 250 mg Capsule", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "ACT-129968", 
            "Pharmacokinetics", 
            "Safety", 
            "Tolerability"
        ], 
        "lastchanged_date": "June 13, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Ulm", 
                    "country": "Germany", 
                    "zip": "D-89081"
                }, 
                "name": "PHAROS GmbH Clinical Research"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Single-center, Open-label, Two-period, Two-treatment, Crossover, Single-dose Study in Healthy Female and Male Subjects to Assess the Pharmacokinetics, Safety, and Tolerability of Two Different Formulations of ACT-129968", 
        "overall_official": {
            "affiliation": "Actelion", 
            "last_name": "Daniela Baldoni, PharmD, PhD", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "July 2011", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "description": "Blood samples for pharmacokinetic analysis taken immediately prior to dosing with ACT-129968, and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 13 hours, 18 hours, 24 hours, 36 hours, and 48 hours, after dosing. AUC0-t calculated on the basis of the blood sampling time points, according to the linear trapezoidal rule using the measured concentration-time values above the limit of quantification (LOQ).", 
                "measure": "The area under the plasma concentration-time curve (AUC) from time zero to time t of the last measured concentration above the limit of quantification (AUC0-t)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }, 
            {
                "description": "Blood samples for pharmacokinetic analysis taken immediately prior to dosing with ACT-129968, and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 13 hours, 18 hours, 24 hours, 36 hours, and 48 hours, after dosing. AUC0-\u221e calculated on the basis of the blood sampling time points, by combining AUC0-t and AUCextra. AUCextra represents an extrapolated value obtained by Ct/\u03bbz, where Ct is the last plasma concentration measured above the LOQ and \u03bbz represents the terminal elimination rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal elimination phase.", 
                "measure": "The area under the plasma concentration-time curve from zero to infinity (AUC0-\u221e)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }, 
            {
                "description": "Blood samples for pharmacokinetic analysis taken immediately prior to dosing with ACT-129968, and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 13 hours, 18 hours, 24 hours, 36 hours, and 48 hours, after dosing. Cmax calculated on the basis of the blood sampling time points.", 
                "measure": "The maximum plasma concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }, 
            {
                "description": "Blood samples for pharmacokinetic analysis taken immediately prior to dosing with ACT-129968, and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 13 hours, 18 hours, 24 hours, 36 hours, and 48 hours, after dosing. tmax calculated on the basis of the blood sampling time points.", 
                "measure": "The time to reach maximum plasma concentration (tmax)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }, 
            {
                "description": "Blood samples for pharmacokinetic analysis taken immediately prior to dosing with ACT-129968, and at 0.5 hours, 1 hour, 1.5 hours, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 9 hours, 13 hours, 18 hours, 24 hours, 36 hours, and 48 hours, after dosing. t\u00bd calculated on the basis of the blood sampling time points. The half-life will be calculated as follows: t\u00bd = ln 2/\u03bbz.", 
                "measure": "The terminal elimination half-life (t\u00bd)", 
                "safety_issue": "No", 
                "time_frame": "2 Days"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01877629"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Blood pressure (systolic and diastolic) measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements recorded from the subject in the supine position after having rested for a 5-minute period.", 
                "measure": "Diastolic blood pressure at baseline and end of study visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 Days"
            }, 
            {
                "description": "Blood pressure (systolic and diastolic) measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements recorded from the subject in the supine position after having rested for a 5-minute period.", 
                "measure": "Systolic blood pressure at baseline and end of study visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 Days"
            }, 
            {
                "description": "Pulse rate measured using an automatic oscillometric device, always on the leading arm (i.e., leading arm right = writing with right hand). Measurements recorded from the subject in the supine position after having rested for a 5-minute period.", 
                "measure": "Pulse rate at baseline and end of study visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 Days"
            }, 
            {
                "description": "Body weight measured using the same weighing scale for all subjects and throughout the study.", 
                "measure": "Body weight at baseline and end of study visit", 
                "safety_issue": "No", 
                "time_frame": "Up to 13 Days"
            }
        ], 
        "source": "Actelion", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Actelion", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Crossover Assignment, Masking: Open Label", 
        "study_type": "Interventional", 
        "verification_date": "June 2013"
    }
}